__timestamp | Exelixis, Inc. | Perrigo Company plc |
---|---|---|
Wednesday, January 1, 2014 | 2043000 | 2613100000 |
Thursday, January 1, 2015 | 3895000 | 2891500000 |
Friday, January 1, 2016 | 6552000 | 3228800000 |
Sunday, January 1, 2017 | 15066000 | 2966700000 |
Monday, January 1, 2018 | 26348000 | 2900200000 |
Tuesday, January 1, 2019 | 33097000 | 3064100000 |
Wednesday, January 1, 2020 | 36272000 | 3248100000 |
Friday, January 1, 2021 | 52873000 | 2722500000 |
Saturday, January 1, 2022 | 57909000 | 2996200000 |
Sunday, January 1, 2023 | 72547000 | 2975200000 |
Monday, January 1, 2024 | 0 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Exelixis, Inc. and Perrigo Company plc from 2014 to 2023. Over this period, Exelixis, Inc. has seen a staggering increase in its cost of revenue, growing by over 3,400%, from approximately $2 million in 2014 to $72 million in 2023. This reflects the company's aggressive expansion and investment in research and development. In contrast, Perrigo Company plc's cost of revenue has remained relatively stable, fluctuating around the $3 billion mark, indicating a consistent operational strategy. This stability suggests a mature market presence and efficient cost management. As the pharmaceutical sector continues to innovate, these insights provide a window into the financial strategies of two key players.
Cost of Revenue Trends: Johnson & Johnson vs Exelixis, Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Exelixis, Inc. vs Pharming Group N.V.
Cost of Revenue: Key Insights for Exelixis, Inc. and Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Exelixis, Inc. and CRISPR Therapeutics AG
Cost Insights: Breaking Down Exelixis, Inc. and MorphoSys AG's Expenses
Cost Insights: Breaking Down Exelixis, Inc. and Wave Life Sciences Ltd.'s Expenses
Analyzing Cost of Revenue: Grifols, S.A. and Perrigo Company plc
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.